Riskpilot← Back to searchSign inGet full accessDERMAI AB
ABDissolvedOrg 5591346969Other research and experimental development on natural sciences and engineering · NACE 7219Est. 20170 employees
Revenue 2023
SEK 0
EBITDA margin
—
-2% vs 2022
Equity ratio
11.1%
Financial strength
Net profit 2023
SEK -192K
+1% vs 2022
| Revenue | SEK 0 | — |
| EBITDA | SEK -116K | -2% |
| Net profit | SEK -192K | +1% |
| Total assets | SEK 450K | -6% |
| Equity | SEK 50K | -74% |
| Employees | 0 | — |
Legal name
DERMAI AB
Org number
5591346969
Legal form
Aktiebolag
NACE code
7219 · Other research and experimental development on natural sciences and engineering
Founded
21 november 2017
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva forskning och produktutveckling inom artificiell intelligens och specialitet Deramatologi samt äga fast- och lös egendom och därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 26 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 178 | 742 | −399 | −114 | −116 |
| Depreciation & amort. | −22 | −19 | −79 | −79 | −79 |
| EBIT | 156 | 723 | −478 | −193 | −195 |
| Net financials | — | — | — | −2 | 3 |
| Profit before tax | 117 | 542 | −235 | −194 | −192 |
| Tax | −25 | −116 | −0 | −0 | −0 |
| Net profit | 92 | 426 | −235 | −194 | −192 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 460 | 1 044 | 530 | 477 | 450 |
| Equity | 198 | 625 | 390 | 196 | 50 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 198 | 176 | 140 | 281 | 400 |
| Total debt | 198 | 176 | 140 | 281 | 400 |
EBITDA margin
-11600000.0%
This company
15.8%
Market median
-73417822% vs market
20192023
Equity ratio
11.1%
This company
38.2%
Market median
-71% vs market
20192023
Return on equity
-384.0%
This company
18.4%
Market median
-2187% vs market
20192023
Net profit margin
-19200000.0%
This company
8.1%
Market median
-237037137% vs market
20192023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192023
Debt / equity
8.00×
This company
0.62×
Market median
-1190% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
CM Chief Executive Officer | Chief Executive Officer | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2024 | |
| Board of Directors | 2024 | |
| Board of Directors | 2024 | |
| Former (3) | ||
| Chairman | 2022 – 2024 | |
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2022 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Skin BidCo AB
DERMAI AB Board members of DERMAI AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Magnus Malcolm Kjellman | Chief Executive Officer | 0 companies |
| Carl Magnus Philip Jerlmyr | Chairman | 0 companies |
| Magnus Gustav Jansson | Chairman | 0 companies |
| Anna Josephine Elonsdotter Borg | Board of Directors | 0 companies |
| Hossein Azizpour | Board of Directors | 0 companies |
| Oscar Samuel Fahlström Lindell | Board of Directors | 0 companies |
| Kevin Charles Smith | Board of Directors | 0 companies |